newsfilter
← Latest News
GlobeNewswire·

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR